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A B S T R A C T   
Background: After an acute myocardial infarction (MI2), patients may develop posttraumatic stress disorder 
(PTSD3). There is evidence for alterations in the hypothalamic–pituitary–adrenal axis in PTSD. An association 
between patients` cortisol level after experiencing an MI and subsequent PTSD symptoms has not been inves-
tigated yet. Therefore, the aim of this study was to examine whether serum cortisol measured in patients 
admitted to hospital for acute coronary care after MI is predictive of PTSD symptoms at three and 12 months 
post-MI, respectively. 
Methods: Patients (N=106) with a verified MI and high risk for the development of MI-induced PTSD symptoms 
were included in the study within 48 hours of hospital admission for acute coronary intervention. Serum cortisol 
was measured from fasting venous blood samples the next morning. Hierarchical regression analysis was used to 
test for an independent contribution of cortisol levels from admission to the Clinician-Administered PTSD Scale 
sum score three and 12 months after discharge from the coronary care unit. 
Results: Hierarchical regression analysis showed that lower serum cortisol levels were significantly associated 
with more severe PTSD symptoms three months (B=-0.002, p=0.042) and 12 months (B=-0.002, p=0.043) post- 
MI. 
Limitations: The generalizability of the findings is limited to patients with high acute peri-traumatic distress and 
without an acute severe depressive episode. The study does not provide any information about the diurnal 
cortisol pattern. 
Conclusion: Lower serum cortisol measured during MI hospitalization may predict more severe MI-induced PTSD 
symptoms three and 12 months after hospital discharge.   
Introduction 
In 2015, an estimated 7.28 million acute myocardial infarctions (MI) 
occurred globally (Roth et al., 2017). MI is a life-threatening event, and 
patients may therefore experience high distress and fear of dying 
(Whitehead et al., 2005). In the aftermath of MI, patients may develop 
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substantial psychological symptoms, including posttraumatic stress 
disorder (PTSD) (Vilchinsky et al., 2017). After experiencing an acute 
coronary syndrome (ACS), approximately 12% of patients show clini-
cally significant PTSD symptoms and around 4% are diagnosed with 
PTSD (Edmondson et al., 2012). Patients with MI-induced PTSD symp-
toms may re-experience the event in the form of intermittent distressing 
thoughts or nightmares. They may avoid reminders of the MI such as 
certain places or activities and may also have problems in concentrating 
or sleeping because of elevated arousal. In addition to impairing pa-
tients’ mental health and daily functioning, MI-triggered PTSD symp-
toms have also been associated with an increased risk of hospital 
readmission due to cardiovascular disease events (Edmondson et al., 
2011; Shemesh et al., 2004; Tsutsui et al., 2017; von Känel et al., 2011) 
and all-cause mortality (Edmondson et al., 2011; Tsutsui et al., 2017). 
Cortisol is a hormone secreted by the adrenals with an important role 
in stress response. Several studies have investigated possible alterations 
in the hypothalamic–pituitary–adrenal (HPA) axis in PTSD, but findings 
regarding cortisol levels are inconsistent as reported by different meta- 
analyses. For example, morning salivary cortisol levels were lower in 
patients with PTSD compared to non-trauma-exposed (NE) controls and 
mentally healthy trauma-exposed patients (TE) (Pan et al., 2018). 
Another meta-analysis found lower morning cortisol and lower 24 hours 
cortisol in patients with PTSD compared to controls consisting of NE, TE 
and patients with unknown trauma-exposure (Schumacher et al., 2019). 
In contrast, there was no difference in cortisol levels between TE and 
PTSD patients with adulthood trauma, and furthermore no difference 
was found between TE and NE (Klaassens et al., 2012). In another study, 
cortisol levels were found to be lower in PTSD patients than in NE, but 
there was no difference between PTSD patients and TE (Meewisse et al., 
2007). Inclusion of patients with ACS-induced PTSD symptoms was not 
reported in any of these meta-analyses (Klaassens et al., 2012; Meewisse 
et al., 2007; Pan et al., 2018; Schumacher et al., 2019). One previous 
study showed an inverse correlation between plasma cortisol and PTSD 
symptoms 18-44 months after MI, after adjusting for depressive symp-
toms (von Känel et al., 2010). 
In addition to studies on cortisol levels in patients with diagnosed 
PTSD, there are also studies on the prognostic value of cortisol levels 
measured shortly after the traumatic event (Bonne et al., 2003; Dela-
hanty et al., 2000; Ehring et al., 2008; McFarlane et al., 2011; Mouthaan 
et al., 2014; Shalev et al., 2008). Some of these studies suggest that a 
lower cortisol level, measured in the close aftermath of a traumatic 
event, might be associated with the development of PTSD and PTSD 
symptoms (Delahanty et al., 2000; Ehring et al., 2008; McFarlane et al., 
2011; Mouthaan et al., 2014). For example, lowered plasma cortisol 
levels measured in the trauma resuscitation room were predictive of 
acute and chronic PTSD symptoms (Mouthaan et al., 2014). This is in 
line with other studies showing an association between lower cortisol 
levels measured shortly after the experience of a traumatic event and 
subsequent PTSD symptoms (Ehring et al., 2008; McFarlane et al., 2011) 
and PTSD diagnosis (Delahanty et al., 2000). Yet, there are also studies 
which reported a lack of association between the initial cortisol level 
and PTSD symptoms at follow-up (Bonne et al., 2003) and PTSD diag-
nosis in civilian trauma victims (Shalev et al., 2008). 
Decreased cortisol may play a role in the development of PTSD 
symptoms (Yehuda, 2002a), further evidenced by studies showing that 
hydrocortisone given shortly after experiencing a traumatic event might 
prevent the development of PTSD (Schelling et al., 2001) and PTSD 
symptoms (Delahanty et al., 2013). 
Whether cortisol levels measured shortly after MI are predictive of 
subsequent MI-triggered PTSD symptoms has not been investigated yet. 
A predictive laboratory marker would be valuable because it might 
allow the early identification of patients at an increased risk of devel-
oping post-MI PTSD symptoms. Based on this knowledge early preven-
tive strategies could potentially be implemented. Therefore, the aim of 
this study was to investigate whether serum cortisol levels at hospital-
ization for MI are predictive of PTSD symptoms 1) three months and 2) 
12 months after hospitalization for acute coronary intervention for MI. 
Methods 
Participants 
Participants in the current study were from the Myocardial Infarction 
– Stress Prevention Intervention (MI-SPRINT) trial that took place be-
tween January 8, 2013 and December 15, 2015 at the Bern University 
Hospital (Meister et al., 2013; von Känel et al., 2018). The aim of this 
randomized, controlled trial (RCT) was to investigate whether an early 
psychological trauma-focused counselling session had a preventive ef-
fect on the development of PTSD following acute MI in a high-risk 
population (Meister et al., 2013; von Känel et al., 2018). The ethics 
committee of the State of Bern approved the research protocol (KEK No. 
170/12). Written informed consent to participate in the study was ob-
tained from all patients included in this RCT. 
Participants of this study were patients aged 18 years or older with 
either an acute ST elevation myocardial infarction (STEMI) or a non- 
STEMI, stable circulatory conditions, and a high risk for the develop-
ment of an MI-triggered PTSD, admitted to the coronary care unit (CCU) 
of the Cardiology Department at the Bern University Hospital. Risk for 
MI-induced PTSD was evaluated with three questions assessing acute 
peri-traumatic distress on a numeric rating scale from 0-10: a) chest pain 
while suffering MI, b) fear of dying until being admitted to the CCU and 
c) feeling of helplessness when confronted with the diagnosis of MI. In 
order to be classified as a high-risk patient, the extent of chest pain had 
to have a score of at least 5 together with a score of at least 5 for fear of 
dying and/or feeling of helplessness. 
Exclusion criteria were insufficient language proficiency in German, 
participation in another RCT, emergency coronary artery bypass graft 
surgery, a current severe depressive episode or another comorbid dis-
ease with an estimated life expectancy under one year in patient’s 
medical history, suicidal ideation in the last two weeks, and lack of 
orientation with regard to situation, place and person. 
Intervention 
Psychological counselling sessions carried out as part of the MI- 
SPRINT trial are described in detail elsewhere (Meister et al., 2013; 
von Känel et al., 2018). In brief, counselling was given by study thera-
pists (i.e., doctoral students in psychology or medicine) within 48 hours 
after admission to the CCU. The verum group was given trauma-focused 
counselling consisting of extensive information about the development, 
symptomatology and treatment of PTSD and the concept of an MI as a 
traumatic experience. The control group was given information on the 
general role of psychological stress in cardiovascular disease and psy-
chological stress management tools. The duration of each counselling 
session was 45 minutes. In both groups, participants received an infor-
mation booklet illustrating the content of the respective counselling 
session. 
Measurements 
Measurements were carried out at three different time points (Fig. 1): 
1. within 48 hours of hospitalization, when patients had reached stable 
circulatory condition, with one single blood sample the next morning 
after the counselling session took place (admission); 2. three months 
after discharge from the CCU (three-month follow-up) and 3. 12 months 
after discharge from the CCU (12-month follow-up). 
Posttraumatic stress 
According to the 5th edition of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-5) (American Psychiatric Association, 2013), 
PTSD is characterized by four different symptom clusters (i.e., intrusion, 
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avoidance, negative alterations in cognitions and mood and alterations 
in arousal and reactivity) which may occur after experiencing a trau-
matic event. For a diagnosis of PTSD to be made, the duration of 
symptoms must be at least one month and there must be clinically 
relevant distress or impaired daily functioning (American Psychiatric 
Association, 2013). 
To evaluate posttraumatic stress, we used the validated German 
version (Schnyder and Moergeli, 2002) of the Clinician-Administered 
PTSD Scale (CAPS) (Blake et al., 1995). CAPS refers to the PTSD 
criteria of DSM-IV (American Psychiatric Association, 1994) since the 
MI-SPRINT trial was planned before the introduction of DSM-5. 
Seventeen possible symptoms of PTSD are looked for which belong to 
one of the three symptom clusters of re-experiencing, avoidance/ 
numbing or hyperarousal. For each symptom, frequency and intensity 
between 0 (=never) and 4 (=almost always) were assessed. For a 
symptom to be present, the frequency needs to have at least a value of 1 
and the intensity a value of at least 2. CAPS sum score can range from 
0 to 136. In this study, the CAPS sum scores recorded at three-month and 
12-month follow-up were included as outcome variables in the hierar-
chical regression analysis. In this sample, Cronbach’s α for the CAPS sum 
score was 0.81 at three-month follow-up and 0.71 at 12 months, indi-
cating good and acceptable internal consistency, respectively. 
Cortisol 
Cortisol (nmol/L) was measured in fasting venous blood samples 
taken at 6 am, the morning after the counselling session had taken place. 
For reasons of logistics or patient care, there were deviations in the 
measuring time in certain cases (n=36). Specific collection times were 
between midnight and 6 am (n=19), at 6 am (n=68), between 6 am and 
8 am (n=6) and between 11 am and 6 pm (n=10). For the same reasons 
as mentioned above, non-fasting blood samples were taken from six 
participants. The serum cortisol samples were analyzed by an electro- 
chemiluminescence immunoassay on a Cobas analyzer (Roche Di-
agnostics, Switzerland). All measurements were carried out by an 
accredited laboratory (Institute of Clinical Chemistry, Bern University 
Hospital). 
Methods 
Covariates were selected a priori based on a literature search and 
theoretical considerations. 
Sociodemographic factors 
Information on age and gender was obtained from patients’ hospital 
charts. Patients were asked about their highest level of education by the 
study therapist at admission. A distinction was made between four 
different levels of education: 1: lower than apprenticeship or vocational 
school; 2: apprenticeship or vocational school; 3: high school gradua-
tion; 4: university graduation, including applied sciences (Bopp et al., 
2003). 
Medical history 
At admission, patients were asked whether they had ever suffered 
from depression in the past. To assess previous posttraumatic experi-
ences in patients’ lives with possible PTSD symptoms in the last three 
months before the MI-hospitalization, three questions from the Struc-
tured Clinical Interview for DSM-IV-PTSD (Wittchen and Fydrich, 1997) 
were asked at admission. Information was obtained from patients on 
experience of traumatic events before being admitted to hospital for 
acute coronary treatment for MI and if any, whether there had been 
moments of re-experiencing such events in nightmares, flashbacks or 
thoughts and if these moments had occurred in the last three months 
before hospitalization for MI. It has been shown that three “yes” answers 
to these questions correctly diagnosed 97% of PTSD cases (Franklin 
et al., 2002). 
The German version of the four-item Jenkins Sleep Questionnaire 
(Jenkins et al., 1988) was used to evaluate the subjective sleep quality in 
four weeks prior to hospitalization for MI. Participants were asked about 
a) difficulties falling asleep; b) waking up at night; c) waking up at night 
with troubles falling asleep again and d) feeling tired after an usual 
amount of sleep. Response options were: 0: not at all; 1: 1–3 days; 2: 4–7 
days; 3: 8–14 days; 4: 15–21 days and 5: 22–28 days. For the analysis, 
the mean score of the four items (between 0 and 5) was calculated. 
Objective indices of the MI severity 
For evaluating the severity of MI, the Global Registry of Acute Cor-
onary Event (GRACE) risk score was used (Fox et al., 2006). The GRACE 
risk score predicts the risk of death or MI within six months after 
admission for an ACS (Fox et al., 2006). The score includes the following 
variables: age, heart rate, systolic blood pressure, serum creatinine, 
elevated cardiac enzymes, Killip class, cardiac arrest and ST-segment 
deviation at admission (Fox et al., 2006). Another variable used to 
objectify the severity of the MI was the need for resuscitation at hospi-
talization (by cardioversion or mechanical). 
Fig. 1. Illustration of the different study time points.  
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Intervention 
Since the MI-SPRINT trial aimed to investigate whether a trauma- 
focused counselling session prevents the development of an MI- 
induced PTSD, the type of intervention was also taken into account. 
Statistical analysis 
For the statistical analysis, IBM SPSS Statistics for Windows, Version 
25.0 (IBM Corp., Armonk, NY) was used. The significance level was set 
at p<0.05 (two-tailed). Due to a number of missing values for the 12- 
month follow-up, we analyzed only the data of participants who 
completed the CAPS after 12 months (N=106) (Fig. 2). The CAPS sum 
Fig. 2. Flow diagram for the included study participants (N=106).  
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score at the three-month follow-up was not assessed in two of these 106 
subjects. Cortisol values at admission were missing in three cases. In-
formation about the highest level of education, history of depression and 
about sleep quality were missing in one case each. The GRACE risk score 
was not calculated for five patients. In eight participants, there was no 
information about PTSD in the past. All these missing values were 
replaced by the expectation maximization algorithm (EM). 
Normal distribution was tested with the Kolmogorov-Smirnov test. 
Group differences in cortisol levels were calculated using Student’s t-test 
and analysis of variance (ANOVA). 
To approximate a normal distribution, CAPS sum scores from the 
three- and 12-month follow-up were square root transformed for the 
hierarchical regression analysis. Hierarchical regression analysis with 
the stepwise method was used to test for an independent contribution of 
cortisol levels at admission to the CAPS sum score of the three- and 12- 
month follow-up. We defined the CAPS sum score of the three-month 
follow-up and of the 12-month follow-up as the dependent variable in 
two separate regression models. We added the variables to the model in 
three blocks. In a first step, we entered demographic variables (age and 
sex), the highest level of education and the variable intervention (i.e., 
trauma-focused or stress-focused counselling session). The second block 
consisted of objective indices of severity of MI (i.e., GRACE risk score 
and need of resuscitation), variables of the medical history (i.e., history 
of depression, history of PTSD and sleep quality). Cortisol levels 
measured at admission were entered in the third step. Linearity and 
homoscedasticity were approved by means of scatter plots. Exclusion of 
autocorrelation was done by interpreting Durbin Watson statistics. We 
used variance inflation factor to check for the absence of multi-
collinearity. Cook’s distance gave no concern of influential outliers. 
Results 
Patient characteristics 
Patient characteristics are summarized in Table 1. All patients were 
of Caucasian ethnicity. Patients were predominantly male (83%), had a 
STEMI (69.8%) and had mid-to-high educational level; 25.5% had a 
history of depression. 
Cortisol 
Mean cortisol was 492.52 nmol/L (SD: 181.85). Cortisol was normal 
distributed (p=0.096). Neither specific collection time (all p-val-
ues>0.05) nor fasting state (p=0.90) were associated with serum 
cortisol levels. Likewise, the intake of glucocorticoids (n=3) was not 
associated with cortisol levels (p=0.62). 
Hierarchical regression analysis for CAPS sum score at three-month 
follow-up 
Table 2 shows the results for the hierarchical regression analysis with 
the three models (1a-c). In model 1a, none of the entered variables was 
significantly associated with the CAPS sum score. In model 1b, the 
variable sleep quality (i.e., the mean score of the Jenkins Sleep Ques-
tionnaire) significantly contributed to the outcome (B=0.392, 
p=0.004). In model 1c, age (B=-0.043, p=0.040), level of education 
(B=-0.393, p=0.037) and again sleep quality (B=0.418, p=0.002) were 
significantly related to the outcome. Additionally, cortisol levels were 
significantly and inversely associated with the CAPS sum score (B=- 
0.002, p=0.042). Cortisol explained 3.5% of the total variance after 
taking all covariates into account. The model explained 14.8% of the 
variance in the CAPS sum score. 
Hierarchical regression analysis for CAPS sum score at 12-month follow- 
up 
Table 3 summarizes the results of the hierarchical regression analysis 
with the three models (1a-c). Only gender was significantly associated 
with the outcome variable in model 1a. Women scored significantly 
higher on the CAPS sum score than men (B=0.780, p=0.040). In model 
1b, the variable intervention (B=-0.688, p=0.018), history of depression 
(B=0.883, p=0.009) and sleep quality (B=0.232, p=0.049) significantly 
contributed to the CAPS sum score of 12-month follow-up. Participants 
from the verum group (i.e., those with a trauma-focused counselling 
session) showed significantly higher posttraumatic stress symptoms at 
12 months after MI than those in the control group. Patients who had a 
history of depression had significantly higher CAPS sum scores than 
those without a history of depression. In the final model (1c) age (B=- 
0.040, p=0.029), intervention (B=-0.713, p=0.013), history of depres-
sion (B=0.980, p=0.004) and sleep quality (B=0.255, p=0.029) were 
significantly related with the outcome. Again, participants in the verum 
group and those with a history of depression showed a higher CAPS sum 
score. Cortisol was an independent predictor for the CAPS sum score in 
the final model 1c (B=-0.002, p=0.043), explaining 3.2% of the total 
variance of the CAPS sum score from 12-month follow-up after taking all 
covariates into account. The final model explained 20% of the variance 
in the CAPS sum score at 12 months. 
Discussion 
We found that serum cortisol levels measured in the close aftermath 
of MI were inversely and significantly associated with MI-induced PTSD 
symptoms measured three and 12 months later in patients at high-risk to 
develop PTSD. The total variance of the CAPS sum score explained by 
the final model in both hierarchical regression analyses was rather 
Table 1 
Characteristics of Study Participants (N=106)  
Characteristics Mean ± Standard 
Deviation 
n (%) 
Age, years 59.7±9.9  
Male gender  88 (83) 
Intervention, verum  59 
(55.7) 
Intervention, control  47 
(44.3) 
Highest level of education: lower than 
apprenticeship or vocational school  
11 
(10.4) 
Highest level of education: apprenticeship or 
vocational school  
76 
(71.7) 
Highest level of education: high school 
graduation  
3 (2.8) 
Highest level of education: university 
graduation, including applied sciences  
16 
(15.1) 
STEMI  74 
(69.8) 
Non-STEMI  32 
(30.2) 
GRACE score 104.2±25.8  
Need for resuscitation  7 (6.6) 
Need for resuscitation, cardioversion  7 (6.6) 
Need for resuscitation, mechanical  0 (0) 
History of depression  27 
(25.5) 
History of PTSD  7 (6.6) 
Mean score in the Jenkins Sleep Questionnaire 1.49±1.22  
CAPS sum score, 3-month follow-up 11.34±11.22  
CAPS sum score, 12-month follow-up 9.44±8.67  
Cortisol, nmol/L 492.52±181.85  
Verum, study group with trauma-focused counselling; Control, study group with 
psychological stress counselling; STEMI, ST-Elevation Myocardial Infarction; 
GRACE, Global Registry of Acute Coronary Events; PTSD, posttraumatic stress 
disorder; CAPS, Clinician-Administered PTSD Scale. Continuous variables are 
given as mean values with standard deviation. 
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modest; furthermore, the independent contribution of cortisol to the 
CAPS sum scores three- and 12-months post-MI was also small. Never-
theless, this finding is a novelty in patients with ACS-induced PTSD 
symptoms and it concurs with observations in non-ACS populations. 
Lower plasma cortisol in patients exposed to trauma at initial med-
ical examination was predictive of PTSD symptoms six weeks and six 
months later, controlling for age, gender, injury, admission to intensive 
care unit, time of blood collection and trauma history (Mouthaan et al., 
2014). Another study found lower salivary cortisol measured in the 
emergency room being predictive of higher PTSD symptom severity in 
motor vehicle accident survivors (Ehring et al., 2008). Similarly, sali-
vary morning cortisol measured two days after hospital admission 
correlated inversely with PTSD symptoms six months later in patients 
with a traumatic accident (McFarlane et al., 2011). 
A possible explanation of why decreased cortisol levels may facilitate 
the development of PTSD symptoms is through a reduced down- 
regulation of the sympathetic nervous system (SNS) (Yehuda, 2002b; 
Yehuda and LeDoux, 2007), which is known to have a regulatory role in 
memory consolidation (McGaugh and Roozendaal, 2002). The reduced 
SNS containment due to decreased cortisol might lead to a stronger 
memory consolidation of the traumatic event resulting in intense 
distress feelings; these feelings might alter the perception of the trauma 
and therefore may delay further recovery (Yehuda, 2002b). 
Another theory of the memory-regulating role of glucocorticoids is 
that they may enhance memory consolidation of emotionally arousing 
experiences but later on also reduce memory retrieval after initial 
consolidation (de Quervain et al., 2009). 
Moreover, there is evidence that hydrocortisone given after a trau-
matic event reduces the risk for the development of PTSD in patients 
with septic shock (Schelling et al., 2001) and of PTSD symptoms in 
patients with traumatic injury (Delahanty et al., 2013) or cardiac sur-
gery (Schelling et al., 2004; Weis et al., 2006). Furthermore, a 
meta-analysis found hydrocortisone as being potentially effective in the 
prevention of PTSD development in adults with severe physical illness or 
injury (Astill Wright et al., 2019). Whether this is also a preventive 
option in the case of MI-induced PTSD has, to the best of our knowledge, 
not been investigated yet. Outcome after corticosteroid therapy in MI 
patients is worth investigating further. According to a systematic 
meta-analysis, treatment of MI patients with corticosteroids is not 
harmful (Giugliano et al., 2003) 
As MI-related PTSD symptoms are known to be associated with 
poorer cardiovascular outcome (Edmondson et al., 2011; Shemesh et al., 
2004; Tsutsui et al., 2017; von Känel et al., 2011), it is highly desirable 
to have a preventive strategy at hand. Any reduction in MI-related PTSD 
would contribute not only to improved mental health, but also to a 
better cardiovascular outcome. As yet, this is only a theoretical 
assumption and further studies on serum cortisol levels in post-MI pa-
tients with PTSD symptoms are needed. It would also be useful to have a 
defined cortisol cut-off value that indicates a higher risk of developing 
PTSD, a task for future research. 
Limitations 
There are several limitations to this study. This study is a secondary 
data analysis of the MI-SPRINT RCT. The RCT was primarily designed to 
test a different hypothesis than the one tested in this study. It should be 
kept in mind that all participants got counselling. The generalizability of 
our findings is limited as the MI-SPRINT RCT included patients with 
Table 2 
Hierarchical regression analysis with the Clinician-Administered PTSD Scale 
sum score at three-month follow-up as outcome variable  




B S.E. β p r2 





Gender 0.169 0.428 0.038 0.695 0.001 
Age -0.022 0.016 -0.130 0.183 0.017 
Education 
level 
-0.364 0.197 -0.182 0.068 0.032 
Intervention -0.283 0.329 -0.085 0.391 0.007 





Gender -0.142 0.453 -0.032 0.744 0.001 
Age -0.037 0.021 -0.221 0.078 0.027 
Education 
level  
-0.356 0.188 -0.178 0.061 0.030 
Intervention -0.409 0.324 -0.123 0.211 0.013 
GRACE score 0.009 0.008 0.141 0.265 0.011 
Need for 
resuscitation  
-0.183 0.636 -0.027 0.774 0.001 
History of 
depression  
0.604 0.378 0.159 0.113 0.021 
History of 
PTSD 
-0.279 0.643 -0.042 0.666  0.002 
Sleep quality 0.392 0.132 0.286 0.004 0.073 





Gender -0.337 0.438 -0.076 0.443 0.005 
Age -0.043 0.021 -0.256 0.040 0.035 
Education 
level  
-0.393 0.186 -0.196 0.037 0.037 
Intervention -0.437 0.319 -0.131 0.174 0.015 
GRACE score 0.011 0.008 0.177 0.159 0.016 
Need for 
resuscitation  
-0.361 0.631 -0.054 0.569 0.003 
History of 
depression  
0.715 0.376 0.188 0.060 0.029 
History of 
PTSD 
-0.589 0.650 -0.088  0.367 0.007 
Sleep quality 0.418 0.131 0.305 0.002 0.083 
Cortisol -0.002 0.001 -0.203 0.042 0.035 
GRACE, Global Registry of Acute Coronary Events; PTSD, posttraumatic stress 
disorder. Data are given as unstandardized coefficient B with Standard Error (S. 
E.) and β, standardized β coefficient; predictor variables were entered in three 
blocks (models a-c). 
Table 3 
Hierarchical regression analysis with the Clinician-Administered PTSD Scale 
sum score of 12-month follow-up as outcome variable  




B S.E. β p r2 





Gender 0.780 0.375 0.196 0.040 0.038 
Age -0.030 0.014 -0.199 0.036 0.040 
Education 
level  
-0.105 0.173 -0.058 0.545 0.003 
Intervention -0.515 0.288 -0.171 0.077 0.028 





Gender 0.435 0.382 0.109 0.258 0.010 
Age  -0.035 0.018 -0.231 0.058 0.029 
Education 
level  
-0.118 0.165 -0.065 0.478 0.004 
Intervention  -0.688 0.285 -0.228 0.018 0.046 
GRACE score 0.003 0.007 0.052 0.671 0.001 
Need for 
resuscitation 
0.613 0.559 0.102 0.275 0.010 
History of 
depression  
0.883 0.332 0.257 0.009 0.056 
History of 
PTSD 
0.160 0.565 0.026 0.778 0.001 
Sleep quality 0.232 0.116 0.188 0.049 0.032 





Gender 0.264 0.385 0.066 0.494 0.004 
Age -0.040 0.018 -0.265 0.029 0.038 
Education 
level 
-0.150 0.163 -0.083 0.361 0.006 
Intervention -0.713 0.281 -0.236 0.013 0.049 
GRACE score 0.005 0.007 0.087 0.474 0.004 
Need for 
resuscitation 
0.458 0.555 0.076 0.411 0.005 
History of 
depression 
0.980 0.330 0.285 0.004 0.068 
History of 
PTSD 
-0.112 0.571 -0.019 0.844 0.000 
Sleep quality 0.255 0.115 0.206 0.029 0.038 
Cortisol -0.002 0.001 -0.197 0.043 0.032 
GRACE, Global Registry of Acute Coronary Events; PTSD, posttraumatic stress 
disorder. Data are given as unstandardized coefficient B with Standard Error (S. 
E.) and β, standardized β coefficient; predictor variables were entered in three 
blocks (models a-c). 
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high acute peri-traumatic distress and without an acute severe depres-
sive episode. Furthermore, we sampled serum cortisol only once and 
collected no serial measurements with short intervals which would have 
yielded more reliable cortisol values given the pulsatile release of 
cortisol. Additionally, our study does not provide any information about 
the diurnal cortisol pattern, including awakening response and slope. 
Moreover, a receiver operating characteristic curve would have been 
interesting to define a cortisol cut-off value that is associated with the 
development of a subsequent PTSD. However, this analysis was not 
possible in our study population as there was only one patient who 
fulfilled the criteria for a DSM-IV diagnosis of PTSD. 
Finally, our study did not consider depressive and anxiety symptoms. 
It is known that post-MI patients are at high risk of depressive or anxiety 
disorders (Feng et al., 2016). Possible changes in the HPA-axis activity in 
patients with depression (Malhi and Mann, 2018) or anxiety disorder 
(Vreeburg et al., 2010) have been reported, so future studies should take 
this into account. 
Conclusion 
Taken together, the findings of this study suggest that lower serum 
cortisol levels measured during MI hospitalization are associated with 
more severe PTSD symptoms in post-MI patients three and 12 months 
after discharge from the CCU. These results may have implications for 
early identification of patients suffering from MI who are at risk for the 
development of MI-induced PTSD symptoms. Cortisol levels can easily 
be measured in the clinical setting and therefore, further investigation of 
cortisol levels in patients with MI-induced PTSD symptoms seems 
worthwhile. Future studies need to identify a cortisol cut-off value 
defining patients at high risk for MI-induced PTSD symptoms. In addi-
tion, the findings of the present study suggest that investigation of pa-
tients’ cortisol levels as a possible target for intervention to prevent ACS- 
induced PTSD is warranted. 
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